|
56.8
|
https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
|
N/A
|
21
|
|
40.6
|
https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
|
N/A
|
15
|
|
16.2
|
https://www.fda.gov/news-events/press-announcements/fda-responds-evidence-possible-association-between-autism-and-acetaminophen-use-during-pregnancy
|
N/A
|
6
|
|
13.5
|
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
|
N/A
|
5
|
|
10.8
|
https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-aged-8-years-and-older-glycogen-storage-disease-type-ia
|
N/A
|
4
|
|
10.8
|
https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-pediatric-patients-sanfilippo-syndrome-type
|
N/A
|
4
|
|
8.1
|
https://www.fda.gov/news-events/press-announcements/fda-accelerates-action-treatments-serious-mental-illness-following-executive-order
|
N/A
|
3
|
|
8.1
|
https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-severe-leukocyte-adhesion-deficiency-type-i
|
N/A
|
3
|
|
8.1
|
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-second-treatment-fibrodysplasia-ossificans-progressiva
|
N/A
|
3
|
|
8.1
|
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lurbinectedin-combination-atezolizumab-or-atezolizumab-and-hyaluronidase-tqjs-extensive
|
N/A
|
3
|
|
5.4
|
https://www.fda.gov/tobacco-products/health-effects-tobacco-use/chemicals-tobacco-products-and-your-health
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-neurologic-manifestations-hunter-syndrome
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-third-treatment-fibrodysplasia-ossificans-progressiva
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-pediatric-patients-most-common-form-dwarfism
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/food/alerts-advisories-safety-information/fda-advises-public-not-eat-sell-or-serve-certain-imported-frozen-shrimp-indonesian-firm
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-therapy-treat-ataxia-patients-ataxia-telangiectasia-rare-genetic-disorder
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/food/outbreaks-foodborne-illness/investigation-5-state-outbreak-cyclospora-illnesses-iceberg-lettuce-july-2026
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warning-about-rare-severe-itching-after-stopping-long-term-use-oral-allergy-medicines
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/food/generally-recognized-safe-gras/how-us-fdas-gras-notification-program-works
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/aquastar-usa-corp-recalls-kroger-mercado-frozen-cooked-shrimp-because-possible-health-risk
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/tobacco-products/rules-regulations-and-guidance-related-tobacco-products/fdas-deeming-regulations-e-cigarettes-cigars-and-all-other-tobacco-products
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-subcutaneous-injection
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/news-events/press-announcements/fda-takes-action-make-treatment-available-autism-symptoms
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/southwind-foods-llc-recalls-frozen-shrimp-because-possible-health-risk
|
N/A
|
2
|
|
5.4
|
https://www.fda.gov/advisory-committees/tobacco-products-scientific-advisory-committee/charter-tobacco-products-scientific-advisory-committee
|
N/A
|
2
|
|
2.7
|
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/medical-devices/products-and-medical-procedures/over-counter-otc-medical-devices-considerations-device-manufacturers
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Guidance-for-Industry--Monoclonal-Antibodies-Used-as-Reagents-in-Drug-Manufacturing.pdf
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/food/food-labeling-nutrition/overview-food-labeling
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/Food/IngredientsPackagingLabeling/LabelingNutrition/ucm072999.htm
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/news-events/press-announcements/fda-advances-robust-transparent-post-market-chemical-review-program-keep-food-supply-safe-and
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/drugs/drug-safety-and-availability/fda-qualifies-total-hip-bone-mineral-density-bmd-surrogate-endpoint-osteoporosis-drug-development
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/drugs/science-and-research-drugs/fda-grant-awards-projects-supporting-use-real-world-data-generate-real-world-evidence-regulatory
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/drugs/information-consumers-and-patients-drugs/hiding-plain-sight-7-oh-products
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/tobacco-products/advertising-and-promotion/swedish-match-usa-inc-modified-risk-tobacco-product-mrtp-applications-zyn-products
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/vaccines-blood-biologics/waskyra
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/vaccines-blood-biologics/qivigy
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/tobacco-products/ctp-newsroom/fda-renews-authorization-five-iqos-products-be-marketed-exposure-modification-claims
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/lockout-supplements-issues-voluntary-nationwide-recall-boner-bears-chocolate-syrup-due-undeclared
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm162701.htm
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/continuous-glucose-monitor-receiver-recall-dexcom-inc-removes-certain-dexcom-g6-g7-one-and-one
|
N/A
|
1
|
|
2.7
|
https://www.fda.gov/science-research/science-and-research-special-topics/new-approach-methodologies-nams
|
N/A
|
1
|